一分钟看懂
这是一项关于乳腺癌的I 期研究，登记的药物或干预包括BG-75202；CDK4 Inhibitor；Estrogen Receptor Antagonist；Aromatase Inhibitor，当前状态为招募中。登记地点显示中国北京、重庆、厦门、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BG-75202；CDK4 Inhibitor；Estrogen Receptor Antagonist；Aromatase Inhibitor · I 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出4项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Beijing Cancer Hospital · 北京
- Chongqing University Cancer Hospital · 重庆
- The First Affiliated Hospital of Xiamen University · 厦门
- Sun Yat Sen University Cancer Center Huangpu Branch · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Hunan Cancer Hospital · 长沙
- Jiangsu Province Hospital Longjiang Branch · 南京
- Fudan University Shanghai Cancer Centerpudong · 上海
- Tianjin Medical University Cancer Institute and Hospital · 天津
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · 杭州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Part 1A: Participants with histologically or cytologically confirmed advanced, metastatic breast cancer and other solid tumors who have exhausted, are intolerant of all available standard of care therapies, and/or without available standard of care therapies.
- * Part 1B and Part 2A: Participants with advanced breast cancer with 1 to 3 prior lines of systemic therapy in the metastatic setting. Prior lines in the advanced/ metastatic setting may not exceed 2 lines of chemotherapy (inclusive of antibody-drug conjugate with cytotoxic payload).
- * Parts 2B and 2C: Participants with advanced breast cancer enrolled in regions where cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are not approved and/or not available as the first-line treatment and who are CDK4/6 inhibitor treatment naïve and did not receive any previous systemic treatment for advanced disease.
- * Participants with breast cancer must have histologically or cytologically confirmed advanced breast cancer at the time of most recent testing, based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
- * Female participants with metastatic breast cancer must be postmenopausal or receiving ovarian function suppression treatment.
- * Measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.
- * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- * Adequate organ function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07222267；登记信息更新于 2026-09-28；本站同步于 2026-10-08，中国中心当前名额未经人工确认。